Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1976 1
1984 1
1985 4
1986 15
1987 62
1988 121
1989 255
1990 348
1991 400
1992 407
1993 401
1994 414
1995 394
1996 410
1997 332
1998 382
1999 330
2000 315
2001 343
2002 459
2003 413
2004 471
2005 544
2006 504
2007 563
2008 562
2009 435
2010 434
2011 330
2012 289
2013 312
2014 264
2015 204
2016 178
2017 150
2018 135
2019 109
2020 151
2021 125
2022 114
2023 89
2024 41

Text availability

Article attribute

Article type

Publication date

Search Results

11,179 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for erythropoietin human recombinant
Your search for erythropoetin-human-recombinant retrieved no results
Recombinant human erythropoietin in pediatric oncology: a review.
Feusner J, Hastings C. Feusner J, et al. Med Pediatr Oncol. 2002 Oct;39(4):463-8. doi: 10.1002/mpo.10187. Med Pediatr Oncol. 2002. PMID: 12203665 Review.
BACKGROUND: Numerous reports on recombinant human erythropoietin (rHuEPO, epoetin alfa) treatment of cancer-related anemia in adult patients have been published to date. ...CONCLUSIONS: These studies suggested an overall beneficial effect of …
BACKGROUND: Numerous reports on recombinant human erythropoietin (rHuEPO, epoetin alfa) treatment of canc …
Perioperative administration of high-dose recombinant human erythropoietin for delayed graft function prevention in kidney transplantation: a meta-analysis.
Vlachopanos G, Kassimatis TI, Agrafiotis A. Vlachopanos G, et al. Transpl Int. 2015 Mar;28(3):330-40. doi: 10.1111/tri.12506. Epub 2015 Jan 6. Transpl Int. 2015. PMID: 25516244 Free article. Review.
Delayed graft function (DGF) due to ischemia-reperfusion injury is a major early complication of kidney transplantation (KT). Recombinant human erythropoietin (rHuEPO) has been shown to exert nephroprotective action in animal models. ...
Delayed graft function (DGF) due to ischemia-reperfusion injury is a major early complication of kidney transplantation (KT). Recombinant …
Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer.
Adamson JW, Ludwig H. Adamson JW, et al. Oncology. 1999;56(1):46-53. doi: 10.1159/000011929. Oncology. 1999. PMID: 9885377 Review.
Recombinant human erythropoietin (Epoetin alfa) is effective in increasing hemoglobin concentration and hematocrit, and in significantly reducing transfusion requirements in the majority of patients with either the anemia of chronic renal failur …
Recombinant human erythropoietin (Epoetin alfa) is effective in increasing hemoglobin concentration and h …
Data from a microdosed recombinant human erythropoietin administration study applying the new biotinylated clone AE7A5 antibody and a further optimized sarcosyl polyacrylamide gel electrophoresis protocol.
Reichel C, Erceg D, Lorenc B, Scheiblhofer V, Farmer L, Zanitzer K, Geisendorfer T, Gmeiner G, Thevis M. Reichel C, et al. Drug Test Anal. 2023 Feb;15(2):163-172. doi: 10.1002/dta.2989. Epub 2021 Jan 21. Drug Test Anal. 2023. PMID: 33450134
Microdoses of Retacrit (epoetin zeta), an EPO biosimilar, were administered intravenously and subcutaneously to human males and females. ...Previous studies applying different electrophoretic techniques and the not further optimized SAR-PAGE protocol revealed consid …
Microdoses of Retacrit (epoetin zeta), an EPO biosimilar, were administered intravenously and subcutaneously to human males an …
Roxadustat for anemia in patients with end-stage renal disease incident to dialysis.
Provenzano R, Shutov E, Eremeeva L, Korneyeva S, Poole L, Saha G, Bradley C, Eyassu M, Besarab A, Leong R, Liu CS, Neff TB, Szczech L, Yu KP. Provenzano R, et al. Nephrol Dial Transplant. 2021 Aug 27;36(9):1717-1730. doi: 10.1093/ndt/gfab051. Nephrol Dial Transplant. 2021. PMID: 33629100 Clinical Trial.
Roxadustat was non-inferior [least squares mean difference: 0.18 (95% CI 0.08, 0.29)] to epoetin alfa. Percentages of patients with an Hb response were 88.2% and 84.4% in the roxadustat and epoetin alfa groups, respectively. Roxadustat was non-inferior …
Roxadustat was non-inferior [least squares mean difference: 0.18 (95% CI 0.08, 0.29)] to epoetin alfa. Percentages of patients …
Erythropoietin in Friedreich ataxia.
Mariotti C, Nachbauer W, Panzeri M, Poewe W, Taroni F, Boesch S. Mariotti C, et al. J Neurochem. 2013 Aug;126 Suppl 1:80-7. doi: 10.1111/jnc.12301. J Neurochem. 2013. PMID: 23859343 Free article. Review.
Evidence for recombinant human erythropoietin (rHuEPO) in FRDA is based on in vitro studies using mouse neuronal cell lines, human fibroblasts, cardiomyocytes, and primary lymphocytes from FRDA patients or control subjects which showed a dose-dependent …
Evidence for recombinant human erythropoietin (rHuEPO) in FRDA is based on in vitro studies using mouse neuronal cell l …
Use of Aspirin in normalization of recombinant human erythropoietin-mediated hyper-reactivity of platelets in rats.
Soni HM, Vekaria AM, Rath AC, Belemkar S, Jain MR. Soni HM, et al. Indian J Pharmacol. 2014 May-Jun;46(3):328-33. doi: 10.4103/0253-7613.132187. Indian J Pharmacol. 2014. PMID: 24987182 Free PMC article.
OBJECTIVES: The cytokine erythropoietin is the primary stimulator of erythropoiesis and recombinant human erythropoietin (rHuEPO), which is widely used in the treatment of anemia associated with advanced chronic kidney disease (CKD). ...
OBJECTIVES: The cytokine erythropoietin is the primary stimulator of erythropoiesis and recombinant human erythropoi …
Recombinant erythropoietin in autoimmune hemolytic anemia with inadequate bone marrow response: a prospective analysis.
Fattizzo B, Pedone GL, Brambilla C, Pettine L, Zaninoni A, Passamonti F, Barcellini W. Fattizzo B, et al. Blood Adv. 2024 Mar 12;8(5):1322-1327. doi: 10.1182/bloodadvances.2023011798. Blood Adv. 2024. PMID: 38029356 Free PMC article.
Up to 30% of patients with autoimmune hemolytic anemia (AIHA) show inadequate bone marrow (BM) compensatory response with inappropriately low levels of reticulocytes and endogenous erythropoietin. Ineffective BM compensation is associated with more severe anemia, transfusi …
Up to 30% of patients with autoimmune hemolytic anemia (AIHA) show inadequate bone marrow (BM) compensatory response with inappropriately lo …
11,179 results
You have reached the last available page of results. Please see the User Guide for more information.